D017338Chemicals & DrugsD03.633.100.759.590.138.300.200D03.633.100.759.590.138.325.075D13.570.230.229.075D13.570.583.138.300.200D13.570.583.138.325.075D13.570.800.096.300.20019350.984479Cladribineprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson31753931Abboud R, Chendamarai E, Rettig MP, Trinkaus KM, Riedell PA, Abboud CN, Ghobadi A, Pusic I, Stockerl-Goldstein K, Schroeder MA, Vij R, Westervelt P, DiPersio JF, Uy GLHaematologicaSelinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica. 2020 08; 105(8):e404-e407.Haematologica2019-11-21T00:00:002019Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.15349753Odenike OM, Sobecks RM, Janisch L, Huo D, Zimmerman TM, Daugherty CK, Ratain MJ, Larson RACancer chemotherapy and pharmacologyA phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemother Pharmacol. 2004 Dec; 54(6):553-61.Cancer Chemother Pharmacol2004-09-02T00:00:002004A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.12592330Byrd JC, Peterson B, Piro L, Saven A, Vardiman JW, Larson RA, Schiffer CLeukemiaA phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia. 2003 Feb; 17(2):323-7.Leukemia2003-02-01T00:00:002003A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.Medicine-Hematology and Oncology18509168Golomb HMJournal of clinical oncology : official journal of the American Society of Clinical OncologyHairy cell leukemia: treatment successes in the past 25 years. J Clin Oncol. 2008 Jun 01; 26(16):2607-9.J Clin Oncol2008-06-01T00:00:002008Hairy cell leukemia: treatment successes in the past 25 years.0.7544570.0096116119research area of0.7396710.026759225subject area forNeurologyUniversity of ChicagoRichard A.LarsonRichard A. Larson41.78927490000000-87.601250000000001169Larson, Richard A.ProfessorAnthony T.RederAnthony T. Reder41.78927490000000-87.601250000000001239Reder, Anthony T.ProfessorMark J.RatainMark J. Ratain41.78927490000000-87.601250000000001401Ratain, Mark J.ProfessorHarvey M.GolombHarvey M. Golomb41.78927490000000-87.601250000000002105Golomb, Harvey M.ProfessorOlatoyosiOdenikew21tDq8cEun5hHlsaUXv9Gq0+s+oOlatoyosi Odenike41.78927490000000-87.60125000000000399Odenike, OlatoyosiProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessor15068894Nabhan C, Gartenhaus RB, Tallman MSLeukemia researchPurine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res. 2004 May; 28(5):429-42.Leuk Res2004-05-01T00:00:002004Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.